NET ASSET VALUE 2024 06 30
On the 30 June 2024 Flerie AB's ("Flerie") Net Asset Value (NAV) was SEK 4,380 million and NAV per share was SEK 0.561.
| Allocation of net asset value | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 471 | 0.060 | 10.8% |
| Xspray Pharma | 17% | 461 | 0.059 | 10.5% |
| Empros Pharma | 79% | 204 | 0.026 | 4.7% |
| KAHR Medical | 31% | 200 | 0.026 | 4.6% |
| Atrogi | 34% | 154 | 0.020 | 3.5% |
| Microbiotica | 11% | 134 | 0.017 | 3.1% |
| Xintela | 56% | 105 | 0.013 | 2.4% |
| Mendus | 24% | 103 | 0.013 | 2.4% |
| Geneos Therapeutics | 12% | 102 | 0.013 | 2.3% |
| Lipum | 57% | 98 | 0.013 | 2.2% |
| Toleranzia | 58% | 76 | 0.010 | 1.7% |
| Synerkine Pharma | 43% | 52 | 0.007 | 1.2% |
| AnaCardio | 19% | 52 | 0.007 | 1.2% |
| Egetis Therapeutics | 2% | 34 | 0.004 | 0.8% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.004 | 0.7% |
| Vitara Biomedical | 5% | 28 | 0.004 | 0.6% |
| Sixera Pharma | 23% | 26 | 0.003 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.002 | 0.4% |
| Amarna Therapeutics | 60% | 12 | 0.001 | 0.3% |
| Strike Pharma | 14% | 6 | 0.001 | 0.1% |
| EpiEndo Pharmaceuticals | 10% | 0 | 0.000 | 0.0% |
| Total | 2,365 | 0.303 | 54.0% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 0.024 | 4.3% |
| Symcel | 31% | 169 | 0.022 | 3.9% |
| Nanologica | 39% | 95 | 0.012 | 2.2% |
| A3P Biomedical | 8% | 75 | 0.010 | 1.7% |
| Provell Pharmaceuticals | 72% | 67 | 0.009 | 1.5% |
| Chromafora | 32% | 53 | 0.007 | 1.2% |
| Frontier Biosolutions | 2% | 19 | 0.002 | 0.4% |
| Bohus Biotech | 45% | 17 | 0.002 | 0.4% |
| Total | 683 | 0.088 | 15.6% | |
| Limited Partnerships, total | 76 | 0.010 | 1.7% | |
| Assets related to portfolio companies | 376 | 0.048 | 8.6% | |
| Other assets and liabilities | 879 | 0.113 | 20.1% | |
| Net asset value | 4,380 | 0.561 | 100.0% | |
| * indirect shares in Provell Pharmaceuticals |